Figure 7
From: Ebselen analogues delay disease onset and its course in fALS by on-target SOD-1 engagement
Mean plasma concentration–time profiles and Pharmacokinetic parameters of MR6-26-2. Mean plasma concentration–time profiles of MR6-26-2 after single IV and PO dose administrations in female CD1 mice. Pharmacokinetic parameters of MR6-26-2 after an oral dose of 30 mg/kg (top table) and an IV dose at 1 mg/kg (lower table) in female CD1 mice. F = (AUCINF-PO/mean AUCINF-IV)/(DosePO/DoseIV) × 100%, AUClast was alternatively used for F calculation when AUCINF was not available or beyond 120% of AUClast. The compound were formulated in 5%DMAC + 95% (20% HP-beta-CD in saline) at 0.2 mg/mL for IV dosing and CMC (0.5%), benzyl alcohol (0.5%), Tween 80 (0.4%) and NaCl (0.9%) at 3 mg/mL for PO dosing, respectively. PK parameters were estimated by non-compartmental model using WinNonlin 8.2.
